Page last updated: 2024-12-07

n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107691
SCHEMBL ID4402752
MeSH IDM0120937

Synonyms (15)

Synonym
gtpl1636
(2s)-2-[[(2s)-2-[[2-[[(2s)-2-(di(prop-2-enyl)amino)-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
ici-174,864
PDSP2_001212
PDSP1_001228
ici 174864
n,n-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine
l-leucine, n,n-di-2-propenyl-l-tyrosyl-2-methylalanyl-l-phenylalanyl-
n,n-diallyl-tyr-aib-phe-leu
l-leucine, n-(n-(n-(n,n-di-2-propenyl-l-tyrosyl)-2-methylalanyl)-l-phenylalanyl)-
(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid
SCHEMBL4402752
Q27078028
n-(2-{[2-({2-[di(prop-2-en-1-yl)amino]-1-hydroxy-3-(4-hydroxyphenyl)propylidene}amino)-1-hydroxy-2-methylpropylidene]amino}-1-hydroxy-3-phenylpropylidene)leucine
DTXSID101008761

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
") injected 1 min before each agonist produced a significant parallel shift to the right of the dose-response curves for morphine and DAMGO, but only partly antagonized the effects of DADLE and DSLET."( Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats.
La Regina, A; Petrillo, P; Sbacchi, M; Tavani, A, 1990
)
0.28
" morphine dose-response line."( Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction.
Jiang, Q; Porreca, F; Tallarida, RJ, 1990
)
0.28
" The slopes of the dose-response lines were parallel, but the delta compound was about 250 times less potent than DAMGO."( Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides.
Kiritsy-Roy, JA; Marson, L; Van Loon, GR, 1989
)
0.28
", DPDPE displaced the morphine dose-response line to the left and also potentiated the effects of normorphine and etorphine."( Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
Nunan, L; Porreca, F; Sheldon, RJ, 1989
)
0.28
" Antinociceptive dose-response curves were constructed for mu ([D-Ala2,NMePhe4,Gly-ol]enkephalin, DAGO; morphine) and delta ([D-Pen2,D-Pen5]enkephalin, DPDPE)-agonists in the absence, and in the presence of the mu non-surmountable antagonist, beta-funaltrexamine (beta-FNA) or the delta-antagonist ICI 174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH, where Aib is alpha-amino-isobutyric acid)."( Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
Heyman, JS; Mosberg, HI; Mulvaney, SA; Porreca, F, 1987
)
0.27
" The dose-response curves of the preferential mu- ligands morphine and [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO) were shifted by naloxone at low doses but not by ICI 174,864."( The role of mu- and delta- opioid receptors on the intestinal propulsion in rats.
La Regina, A; Petrillo, P; Sbacchi, M; Tavani, A, 1986
)
0.27
" Incubation of increasing concentrations of ICI 174,864 (10,30,100 and 300 nM) produced a dose-related and parallel rightward displacement of the DPDPE dose-response curve in the MVD."( Studies in vitro with ICI 174,864, [D-Pen2, D-Pen5]-enkephalin (DPDPE) and [D-Ala2, NMePhe4, Gly-ol]-enkephalin (DAGO).
Burks, TF; Hirning, LD; Hruby, VJ; Hurst, R; Mosberg, HI; Porreca, F, 1985
)
0.27
"The effects of the delta-selective antagonist ICI 174864 and naltrexone on the dose-response curves to the mu-selective agonist RX 783006 and D-ala-D-leucine enkephalin (DADL) have been investigated in the rat isolated vas deferens preparation (RVD) set up in Krebs solution containing half the normal Ca++ concentration."( Delta receptors in the rat vas deferens.
Carter, A; Smith, CF, 1986
)
0.27
" Diazoxide (2 microg/mouse) shifted morphine's dose-response curve 47-fold, while levcromakalim (0."( ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
Lohmann, AB; Welch, SP, 1999
)
0.3
" These two compounds also exhibited nanomolar potencies in dose-response experiments performed on wild-type, M262T, Y308H, and C328R CAM receptors."( Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors.
Befort, K; Décaillot, FM; Filliol, D; Kieffer, BL; Lazarus, LH; Schiller, PW; Schmidhammer, H; Tryoen-Tóth, P, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1346406Rat delta receptor (Opioid receptors)1999British journal of pharmacology, Oct, Volume: 128, Issue:3
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (209)

TimeframeStudies, This Drug (%)All Drugs %
pre-199071 (33.97)18.7374
1990's106 (50.72)18.2507
2000's27 (12.92)29.6817
2010's4 (1.91)24.3611
2020's1 (0.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.81 (24.57)
Research Supply Index5.42 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other222 (98.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]